1. Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, […]readmore
Tags : Akili
Shots: The FDA’s De novo clearance is based on five clinical studies in 600+ children diagnosed with ADHD, which demonstrated an improved measure of attention. After 4wks., one-third of children […]readmore
Shots: Akili to receive $20M upfront, $105M as development & commercialization milestones, making the total the deal value $125M & royalties on sales of the products. Shionogi to get exclusive […]readmore